Found: 22
Select item for more details and to access through your institution.
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 1, doi. 10.1111/apt.17584
- Publication type:
- Article
AP&T: Editors' declarations of interest.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 4, doi. 10.1111/apt.18030
- Publication type:
- Article
Meta‐analysis: Intestinal ultrasound to evaluate colonic contents and constipation.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 6, doi. 10.1111/apt.18029
- By:
- Publication type:
- Article
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 17, doi. 10.1111/apt.18042
- By:
- Publication type:
- Article
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 33, doi. 10.1111/apt.18011
- By:
- Publication type:
- Article
Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 43, doi. 10.1111/apt.18013
- By:
- Publication type:
- Article
The use of opioids nine months after surgery for Crohn's disease – a nationwide cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 52, doi. 10.1111/apt.18014
- By:
- Publication type:
- Article
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 61, doi. 10.1111/apt.18015
- By:
- Publication type:
- Article
The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 70, doi. 10.1111/apt.18019
- By:
- Publication type:
- Article
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Another brick in the CDST wall.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Another brick in the CDST wall: Authors' reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Editorial: Has MetALD met the presumption?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Has MetALD met the presumption? Authors' reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 101, doi. 10.1111/apt.18049
- By:
- Publication type:
- Article
Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 103, doi. 10.1111/apt.18057
- By:
- Publication type:
- Article
Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 105, doi. 10.1111/apt.18044
- By:
- Publication type:
- Article
Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 1, p. 107, doi. 10.1111/apt.18067
- By:
- Publication type:
- Article